News
Gilead Sciences' unit Kite Pharma said on Thursday it will acquire privately-held biotech firm Interius BioTherapeutics for $350 million in cash to advance CAR T-cell cancer therapies that are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback